Heparin/Low Molecular Weight Heparin and Fondaparinux Pharmacology and Pharmacotherapy

If desired, “bundle” pricing can be obtained by registering for the activities in groups. It consists of thirteen anticoagulation activities in our online selection.

You may register for individual topics at $17/CE Credit Hour, or for the Entire Anticoagulation Pre-requisite Series.

Pharmacist General Registration for 13 Anticoagulation Pre-requisite activities-(12 hours of CE)  $140.00

In order to attend the 2-day Anticoagulation Traineeship, you must complete all of the Pre-requisite Series or the equivalent.

Anticoagulation Traineeship at the University of Connecticut Health Center, Farmington, CT

The University of Connecticut School of Pharmacy and The UConn Health Center Outpatient Anticoagulation Clinic have developed 2-day practice-based ACPE certificate continuing education activity for registered pharmacists and nurses who are interested in the clinical management of patients on anticoagulant therapy and/or who are looking to expand their practice to involve patient management of outpatient anticoagulation therapy. This traineeship will provide you with both the clinical and administrative aspects of a pharmacist-managed outpatient anticoagulation clinic. The activity features ample time to individualize your learning experience. A “Certificate of Completion” will be awarded upon successful completion of the traineeship.

More Information About Traineeship

To receive CE Credit go to Blue Button labeled "take Test/Evaluation" at the top of the page.

Type in your NABP ID, DOB and the session code for the activity.  You were sent the session code in your confirmation email.

Download

1. You get a phone call from a nurse, concerned that her patient with a new blood clot and being treated with heparin is going for dialysis today. She is unsure of how this will affect the patient’s heparin therapy. You respond:
a. You advise the nurse the patient will require an additional bolus dose of heparin after dialysis.
b. As heparin is contraindicated in patient’s on dialysis, you contact the doctor and get the order changed to LMWH.
c. You advise the nurse that dialysis will not affect heparin levels and it is safe to continue therapy without any intervention.
d. You advise the nurse to increase the heparin rate during dialysis.
e. As heparin is contraindicated in patient’s on dialysis, you contact the doctor and get the order changed to argatroban.

2. The following is true regarding low molecular weight heparins, except:
a. LMWH share a common pentasaccharide sequence that enables binding to antithrombin and thrombin
b. Protamine will not completely reverse LMWH effects
c. Dose adjustments are necessary for CrCl <30 ml/min d. Due to longer half life, once or twice daily dosing is possible e. All of the above are true 3. Low molecular weight heparins are approved for all of the following indications, except: a. Prevention of venous thromboembolism b. Treatment of venous thromboembolism c. Anticoagulation in patients with a history of HIT d. Acute coronary syndromes e. All of the above 4. TY, a 70 year old male is admitted to your hospital with an community acquired pneumonia. He is started on IV antibiotics, albuterol nebulizers, and IV fluids. He has no allergies. His INR on admission is 1.1. His BUN/Scr = 30/2.5 He is 5’5” and 75 kg. On interdisciplinary rounds, the attending physician asks for any pharmacological recommendations for this patient. You suggest that VTE prophylaxis should be considered if the patient does not have any contraindications to it. The patient does not have any contraindications, and the physician asks for your recommendation for choice of therapy. The most appropriate recommendation is: a. Enoxaparin 40mg SC daily b. IV Heparin per thromboembolic protocol c. Fondaparinux 2.5mg SC daily d. Enoxaparin 30mg SC daily e. Tinzaparin 13,125 anti Xa international units SC daily 5. The following are true about BOTH LMWH and fondaparinux, except: a. Dose adjustment or avoidance of use is necessary in patients with impaired renal function b. Anti Xa testing is recommended for most patients, and should be drawn on days 2 and 4 of therapy c. Active bleeding is a contraindication for use d. Both are associated with lower risk for development of HIT vs. heparin e. Both are indicated for the treatment and prophylaxis of VTE

Vitamin K Antagonist Pharmacology, Pharmacotherapy and Pharmacogenomics – 1 hour

Anticoagulation Management Pearls - 1 hour

Direct Oral Anticoagulants and Factor IIa and Xa Inhibitors – 1 hour

Laboratory Monitoring of Anticoagulation – 1 hour

Heparin/Low Molecular Weight Heparin and Fondaparinux Pharmacology and Pharmacotherapy – 0.5 hours

Developing an Anticoagulation Clinic – 1.0 hour

Pharmacist Reimbursement for Anticoagulation Services – 0.5 hour

Risk Management in Anticoagulation – 1 hour

Perioperative Management of Warfarin Interruption – 1 hour

Hypercoagulable States – 1 hour

Challenging Topics in Anticoagulation – 1 hour

Available Strategies to Reverse Anticoagulation Medications - 1 hour

Case Studies in Drug Interactions with Anticoagulation Therapy – 1 hour